Circadian disruption, sleep loss, and prostate cancer risk: A systematic review of epidemiologic studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 7, 2012, Pages 1002-1011

  Sigurdardottir, Lara G ^a,b   Valdimarsdottir, Unnur A ^a,c,d   Fall, Katja ^a,c,d   Rider, Jennifer R ^d,e   Lockley, Steven W ^e,f   Schernhammer, Eva ^d,e   Mucci, Lorelei A ^a,d,e  

^a UNIVERSITY OF ICELAND   (Iceland)

^b ICELANDIC CANCER SOCIETY   (Iceland)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CIRCADIAN RHYTHM SLEEP DISORDER; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SHIFT WORKER; SLEEP QUALITY; SYSTEMATIC REVIEW;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; SLEEP DISORDERS, CIRCADIAN RHYTHM; WORK SCHEDULE TOLERANCE;

EID: 84863601152     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0116     Document Type: Review

References (57)

1. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007;8:1065-6.
2. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005;41:2023-32. (Pubitemid 41557687)
3. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology 2006;17:108-11.
4. Arendt J. Melatonin and the pineal gland: influence on mammalian seasonal and circadian physiology. Rev Reprod 1998;3:13-22. (Pubitemid 28062305)
5. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649-61. (Pubitemid 37280160)
6. Filipski E, Levi F. Circadian disruption in experimental cancer processes. Integr Cancer Ther 2009;8:298-302.
7. Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res Treat 2011;127:531-40.
8. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 2006;97:589-96. (Pubitemid 44056606)
9. Chen-Goodspeed M, Lee CC. Tumor suppression and circadian function. J Biol Rhythms 2007;22:291-8.
10. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010;49:60-8.
11. Kneisley LW, Moskowitz MA, Lynch HG. Cervical spinal cord lesions disrupt the rhythm in human melatonin excretion. J Neural Transm Suppl 1978:311-23.
12. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 2000;85:2189-96. (Pubitemid 32269243)
13. Xi SC, Tam PC, Brown GM, Pang SF, Shiu SY. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 2000;29:172-83.
14. Xi SC, Siu SW, Fong SW, Shiu SY. Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 2001;46:52-61. (Pubitemid 32157776)
15. Siu SW, Lau KW, Tam PC, Shiu SY. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity. Prostate 2002;52:106-22. (Pubitemid 34663323)
16. Lupowitz Z, Zisapel N. Hormonal interactions in human prostate tumor LNCaP cells. J Steroid Biochem Mol Biol 1999;68:83-8. (Pubitemid 29130389)
17. Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 2000;7:347-51.
18. Marelli MM, Limonta P, Maggi R, Motta M, Moretti RM. Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate 2000;45:238-44.
19. Sainz RM, Mayo JC, Tan DX, Leon J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate 2005;63:29-43. (Pubitemid 40365388)
20. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 2009;13:257-64.
21. Toma JG, Amerongen HM, Hennes SC, O'Brien MG, McBlain WA, Buzzell GR. Effects of olfactory bulbectomy, melatonin, and/or pinealectomy on three sublines of the Dunning R3327 rat prostatic adenocarcinoma. J Pineal Res 1987;4:321-38.
22. Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 1999;65:415-20. (Pubitemid 29325284)
23. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95. (Pubitemid 27034965)
24. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011;51:1-16.
25. Nguyen HL, Zucker S, Zarrabi K, Kadam P, Schmidt C, Cao J. Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase. Mol Cancer Res 2011;9:1305-18.
26. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Fluchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992;209:153-67.
27. Bartsch C, Bartsch H, Fluchter SH, Attanasio A, Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J Pineal Res 1985;2:121-32. (Pubitemid 15071911)
28. Shiu SY, Law IC, Lau KW, Tam PC, Yip AW, Ng WT. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype. J Pineal Res 2003;35:177-82. (Pubitemid 37100395)
29. Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 1998;9:490-4. (Pubitemid 28387947)
30. Pukkala E, Verkasalo PK, Ojamo M, Rudanko SL. Visual impairment and cancer: a population-based cohort study in Finland. Cancer Causes Control 1999;10:13-20. (Pubitemid 29134747)
31. Pukkala E, Ojamo M, Rudanko SL, Stevens RG, Verkasalo PK. Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes Control 2006;17:573-6.
32. Flynn-Evans EE, Stevens RG, Tabandeh H, Schernhammer ES, Lockley SW. Total visual blindness is protective against breast cancer. Cancer Causes Control 2009;20:1753-6.
33. Costa G, Haus E, Stevens R. Shift work and cancer - considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health 2010;36:163-79.
34. Kolstad HA. Nightshift work and risk of breast cancer and other cancers-a critical reviewof the epidemiologic evidence. Scand J Work Environ Health 2008;34:5-22. (Pubitemid 351585723)
35. Buja A, Lange JH, Perissinotto E, Rausa G, Grigoletto F, Canova C, et al. Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data. Toxicol Ind Health 2005;21:273-82. (Pubitemid 43088281)
36. Ballard T, Lagorio S, De Angelis G, Verdecchia A. Cancer incidence and mortality among flight personnel: a meta-analysis. Aviat Space Environ Med 2000;71:216-24. (Pubitemid 30131410)
37. Kakizaki M, Inoue K, Kuriyama S, Sone T, Matsuda-Ohmori K, Nakaya N, et al. Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer 2008;99:176-8. (Pubitemid 351920224)
38. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol 2006;164:549-55. (Pubitemid 44412783)
39. Conlon M, Lightfoot N, Kreiger N. Rotating shift work and risk of prostate cancer. Epidemiology 2007;18:182-3. (Pubitemid 46005923)
40. Kubo T, Oyama I, Nakamura T, Kunimoto M, Kadowaki K, Otomo H, et al.Industry-based retrospective cohort study of the risk of prostate cancer among rotating-shift workers. Int J Urol 2011;18:206-11.
41. Kloog I, Haim A, Stevens RG, Portal BA. Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men. Chronobiol Int 2009;26:108-25.
42. Schwartzbaum J, Ahlbom A, Feychting M. Cohort study of cancer risk among male and female shift workers. Scand J Work Environ Health 2007;33:336-43. (Pubitemid 350186761)
43. Pukkala E, Aspholm R, Auvinen A, Eliasch H, Gundestrup M, Haldorsen T, et al. Incidence of cancer among Nordic airline pilots over five decades: occupational cohort study. BMJ 2002;325:567.
44. Band PR, Le ND, Fang R, Deschamps M, Coldman AJ, Gallagher RP, et al. Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Am J Epidemiol 1996;143:137-43. (Pubitemid 26036254)
45. Band PR, Spinelli JJ, Ng VT, Moody J, Gallagher RP. Mortality and cancer incidence in a cohort of commercial airline pilots. Aviat Space Environ Med 1990;61:299-302. (Pubitemid 20210703)
46. Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparen P, Tryggvadottir L, et al. Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol 2009;48:646-790.
47. Bates MN. Registry-based case-control study of cancer in California firefighters. Am J Ind Med 2007;50:339-44. (Pubitemid 46786851)
48. Nicholas JS, Lackland DT, Dosemeci M, Mohr LC Jr, Dunbar JB, Grosche B, et al. Mortality among US commercial pilots and navigators. J Occup Environ Med 1998;40:980-5. (Pubitemid 28533726)
49. Irvine D, Davies DM. British Airways flightdeck mortality study, 1950-1992. Aviat Space Environ Med 1999;70:548-55. (Pubitemid 29254773)
50. Krstev S, Baris D, Stewart PA, Hayes RB, Blair A, Dosemeci M. Risk for prostate cancer by occupation and industry: a 24-state death certificate study. Am J Ind Med 1998;34:413-20. (Pubitemid 28464887)
51. Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab 1991;73:1276-80. (Pubitemid 121000703)
52. Lauderdale DS, Knutson KL, Yan LL, Liu K, Rathouz PJ. Self-reported and measured sleep duration: how similar are they? Epidemiology 2008;19:838-45.
53. Burch JB, Yost MG, Johnson W, Allen E. Melatonin, sleep, and shift work adaptation. J Occup Environ Med 2005;47:893-901. (Pubitemid 41306701)
54. Charles LE, Loomis D, Shy CM, Newman B, Millikan R, Nylander-French LA, et al. Electromagnetic fields, polychlorinated biphenyls, and prostate cancer mortality in electric utility workers. Am J Epidemiol 2003;157:683-91. (Pubitemid 36423081)
55. Wen CP, Tsai SP, Gibson RL. Anatomy of the healthy worker effect: a critical review. J Occup Med 1983;25:283-9. (Pubitemid 13097849)
56. Meijers JM, Swaen GM, Volovics A, Lucas LJ, van Vliet K. Occupational cohort studies: the influence of design characteristics on the healthy worker effect. Int J Epidemiol 1989;18:970-5. (Pubitemid 20030217)
57. Stevens RG. Electric light causes cancer? Surely you're joking, Mr. Stevens. Mutat Res 2009;682:1-6.